Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 in recurrent or metastatic HNSCC
NCT06857279Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HLX43 in head and neck squamous cell carcinoma (HNSCC), sponsored by Henlius. Primary endpoints: Objective Response Rate at 24 weeks and Progression-Free Survival at 14 months. Started Apr 2025; status: recruiting.
02
Drugs
HLX43
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06857279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857279.